Coumadin (Warfarin): A Cardiologist's Guide to Who Still Needs It and Why

For decades, Coumadin (warfarin) was the only oral blood thinner available to prevent strokes and treat blood clots. It was the backbone of anticoagulation in cardiology, and virtually every patient with atrial fibrillation, a deep vein thrombosis, or a pulmonary embolism was placed on it. That changed dramatically starting in 2010 with the arrival of direct oral anticoagulants (DOACs) like apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). These newer medications offered fixed dosing, fewer drug and food interactions, and no need for routine blood monitoring. Within a few years, DOACs became the preferred choice for most patients who need anticoagulation.

But warfarin didn't disappear. It shouldn't have, and it won't. There are specific clinical situations where warfarin remains the only proven option, where DOACs have either failed or have never been adequately tested. As a cardiologist, I still prescribe warfarin regularly, and I want my patients to understand why it's sometimes the right medication for them, even in 2026.

This article is a thorough look at warfarin: how it works, who still needs it, why DOACs can't always replace it, how to manage it safely, and what to expect if you're starting or continuing this medication.

How Warfarin Works

Warfarin is a vitamin K antagonist. To understand what that means, it helps to know a little about how your blood clots. Your liver produces several clotting proteins (called clotting factors), and four of those factors (II, VII, IX, and X) require vitamin K to become active. Vitamin K acts as a cofactor in a chemical reaction that activates these proteins, allowing them to participate in the clotting cascade.

Warfarin works by blocking an enzyme called vitamin K epoxide reductase (VKORC1). This enzyme recycles vitamin K back to its active form after it's been used. When warfarin inhibits VKORC1, your liver can't efficiently reactivate vitamin K, which means those four clotting factors are produced in a partially inactive state. The result is a controlled reduction in your blood's ability to form clots.

This mechanism is elegant but also the source of warfarin's complexity. Because warfarin works through vitamin K, anything that changes your vitamin K levels (diet, antibiotics, other medications, illness) can shift the balance and affect how well the drug is working. That's why warfarin requires regular blood monitoring, something the DOACs do not.

The Rise of DOACs and the Decline of Warfarin

Between 2010 and 2015, four landmark clinical trials reshaped anticoagulation therapy. The RE-LY trial tested dabigatran, ROCKET AF tested rivaroxaban, ARISTOTLE tested apixaban, and ENGAGE AF-TIMI 48 tested edoxaban. All four compared their respective DOAC to warfarin in patients with non-valvular atrial fibrillation. All four demonstrated at least non-inferiority to warfarin for stroke prevention, and several showed superiority for certain endpoints, particularly reduced intracranial hemorrhage.

These results, combined with the practical advantages of DOACs (fixed dosing, no INR monitoring, fewer dietary restrictions), led medical societies worldwide to update their guidelines. By 2019, the American Heart Association, American College of Cardiology, and Heart Rhythm Society gave DOACs a Class I recommendation over warfarin for most patients with atrial fibrillation. Similar shifts occurred for venous thromboembolism treatment.

The result has been a significant and appropriate migration away from warfarin. In most cardiology practices today, including mine, the majority of new anticoagulation prescriptions are for DOACs. But "most" is not "all," and there are patients sitting in front of me every week for whom warfarin is the correct choice.

When Warfarin Is Still the Right Choice

Despite the advantages of DOACs, there are several clinical scenarios where warfarin remains the standard of care, and in some cases, the only safe option. Understanding these situations is important because switching a patient from warfarin to a DOAC when warfarin is actually indicated can be dangerous.

Mechanical Heart Valves

This is the most clear-cut indication for warfarin over DOACs. If you have a mechanical (prosthetic) heart valve, warfarin is the only oral anticoagulant that has been proven safe and effective for you. The RE-ALIGN trial, published in the New England Journal of Medicine in 2013, tested dabigatran in patients with mechanical heart valves and had to be stopped early because of an excess of both thromboembolic events (strokes and valve clots) and bleeding events in the dabigatran group compared to warfarin. The results were unequivocal: DOACs do not work for mechanical valves.

The reason appears to be related to the unique nature of clot formation on mechanical valve surfaces. The thrombosis that occurs on prosthetic materials involves different pathways than the clot formation in atrial fibrillation, and warfarin's broader inhibition of multiple clotting factors provides protection that the more targeted DOACs cannot match. For patients with mechanical valves, the INR target is typically 2.5 to 3.5 depending on valve position and type, and lifelong warfarin therapy is mandatory.

Antiphospholipid Syndrome (APS)

Antiphospholipid syndrome is an autoimmune condition in which your immune system produces antibodies that increase the risk of blood clots in both arteries and veins. It can cause strokes, deep vein thromboses, pulmonary emboli, and pregnancy complications. For patients with APS, particularly those who are "triple positive" (meaning they have all three types of antiphospholipid antibodies: lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies), warfarin remains the recommended anticoagulant.

Several studies, including the TRAPS trial, demonstrated that rivaroxaban was associated with a higher rate of thrombotic events compared to warfarin in triple-positive APS patients. The trial was stopped early for safety concerns. While there is some emerging real-world data suggesting DOACs may be acceptable for single-positive APS patients with venous-only disease, the standard of care for arterial APS and triple-positive APS remains warfarin with an INR target of 2.0 to 3.0.

Rheumatic Mitral Stenosis

Patients with moderate-to-severe mitral stenosis caused by rheumatic heart disease who develop atrial fibrillation were excluded from all four of the major DOAC vs. warfarin trials. This means there is essentially no randomized evidence supporting DOACs in this population. The mechanism of clot formation in rheumatic mitral stenosis (slow blood flow through a narrowed, scarred valve) differs from non-valvular atrial fibrillation, and guidelines continue to recommend warfarin for these patients.

Severe Kidney Disease

All DOACs are cleared to some degree by the kidneys. Patients with severe renal impairment (creatinine clearance below 25-30 mL/min, depending on the specific DOAC) were excluded from the pivotal clinical trials. For patients with advanced chronic kidney disease or those on dialysis, warfarin remains the most commonly used oral anticoagulant because its metabolism does not depend on renal clearance. However, I should note that anticoagulation in dialysis patients is a nuanced and evolving area, and the decision requires careful individualized assessment.

Left Ventricular Thrombus

When a blood clot forms inside the left ventricle of the heart, typically after a large heart attack that damages the heart muscle, warfarin has traditionally been the anticoagulant of choice. While there are some smaller studies suggesting DOACs may be effective in this setting, the evidence base is much stronger for warfarin, and many cardiologists (myself included) still prefer warfarin for at least the initial treatment period. The INR target is 2.0 to 3.0, and treatment duration is typically three to six months with repeat imaging to confirm clot resolution.

Cost and Access Considerations

This is a practical reality that matters. While DOAC prices have come down significantly in recent years (and some now have generics available), warfarin remains one of the cheapest prescription medications available. A 90-day supply of generic warfarin costs a few dollars at most pharmacies. For patients who are uninsured, underinsured, or on fixed incomes, warfarin's affordability is a legitimate factor in treatment decisions, particularly when combined with good INR management.

Understanding INR and How Warfarin Is Monitored

If you're on warfarin, you'll become very familiar with a blood test called the INR (International Normalized Ratio). This test measures how long it takes your blood to clot compared to a standardized reference. A normal INR for someone not on blood thinners is about 1.0. For most patients on warfarin, the target INR is 2.0 to 3.0, meaning your blood takes two to three times longer to clot than normal. For patients with mechanical heart valves, the target is higher: 2.5 to 3.5.

The goal of INR monitoring is to keep you in what's called the therapeutic range. When your INR is below 2.0, you're underanticoagulated and at increased risk for blood clots and strokes. When your INR is above 3.0 (or above 3.5 for mechanical valves), you're overanticoagulated and at increased risk for bleeding. The sweet spot is the range where the medication is providing meaningful protection without excessive bleeding risk.

A quality metric used to evaluate warfarin management is called Time in Therapeutic Range (TTR). This measures what percentage of time your INR stays within the target range. A TTR of 65-70% or higher is considered good control. Studies consistently show that patients with a TTR above 65% have outcomes that are comparable to DOACs, while patients with a TTR below 60% have higher rates of both clotting and bleeding complications. This is why the quality of your warfarin management matters as much as the decision to prescribe it.

When you first start warfarin, your INR will be checked frequently, often every few days, until a stable dose is established. Once you're stable, monitoring typically moves to every two to four weeks. Some patients use home INR testing devices (similar in concept to home glucose monitors) that allow them to check their INR at home and report the results to their doctor. This can improve TTR by allowing more frequent monitoring without the inconvenience of office visits.

Warfarin Dosing: Why It's Different for Everyone

One of the most distinctive features of warfarin is that there is no standard dose. Some patients need 1 mg per day; others need 10 mg or more. This variability is driven by several factors.

Genetics. Two genes play a major role in how your body handles warfarin. The CYP2C9 gene encodes the liver enzyme responsible for breaking down warfarin. Variants in this gene can cause you to metabolize warfarin more slowly, meaning a lower dose will produce a stronger effect. The VKORC1 gene encodes the enzyme that warfarin targets. Variants in this gene affect how sensitive your body is to the drug. Together, these two genes account for roughly 30-40% of the dose variability between patients. The FDA-approved warfarin label includes pharmacogenomic dosing tables, and some centers offer genetic testing to guide initial dosing, though this isn't yet standard practice everywhere.

Diet. Because warfarin works by antagonizing vitamin K, the amount of vitamin K in your diet directly affects the drug's potency. Foods rich in vitamin K include leafy green vegetables (kale, spinach, collard greens, broccoli, Brussels sprouts), green tea, and certain oils (soybean, canola). The key message I give my patients is not to avoid these foods, which are healthy and nutritious, but to keep your intake consistent from week to week. If you eat a large salad with spinach every day, that's fine, as long as you do it consistently so your warfarin dose can be calibrated to account for it. Problems arise when intake fluctuates wildly, like eating no greens for a week and then having a large spinach salad, which can cause your INR to swing unpredictably.

Other medications. Warfarin interacts with a long list of other drugs. Some medications increase warfarin's effect (raising INR and bleeding risk), including many antibiotics (particularly metronidazole, fluconazole, and trimethoprim-sulfamethoxazole), amiodarone, and some pain relievers. Others decrease warfarin's effect (lowering INR and raising clot risk), including rifampin, carbamazepine, and St. John's Wort. Any time a new medication is started or stopped, your INR should be rechecked within a few days.

Age, body weight, and liver function also influence dosing. Older patients and those with liver disease generally require lower doses. Your doctor will adjust your dose based on your INR results, and it may take several weeks to find the right dose when you're first starting.

Bleeding Risk: Understanding and Managing It

The most significant risk of any blood thinner, including warfarin, is bleeding. This is the trade-off at the heart of anticoagulation therapy: we're intentionally reducing your blood's ability to clot in order to prevent dangerous clots (strokes, pulmonary emboli), but that same reduction in clotting ability means you'll bleed more easily if you cut yourself, fall, or develop a GI bleed.

Minor bleeding events like bruising, nosebleeds, and bleeding gums are relatively common and usually manageable. More serious bleeding, particularly gastrointestinal bleeding and intracranial hemorrhage, is the primary safety concern. Your doctor will assess your bleeding risk before starting warfarin using scoring tools like the HAS-BLED score, which considers factors like high blood pressure, abnormal kidney or liver function, prior stroke, prior bleeding history, labile INR, age over 65, and use of medications that promote bleeding (like NSAIDs or antiplatelet drugs).

If you're on warfarin and experience a significant bleeding event, the drug can be reversed. Vitamin K (given intravenously) restores the clotting factors that warfarin suppresses, though it takes several hours to take full effect. For life-threatening bleeding, four-factor prothrombin complex concentrate (4F-PCC) provides immediate reversal by directly replacing the depleted clotting factors. This ability to reverse warfarin quickly and reliably is actually an advantage in emergency situations. (DOACs also have reversal agents now, though availability varies by hospital.)

Practical Tips for Patients on Warfarin

If you're on warfarin, or about to start it, here are the things that will make the biggest difference in your safety and success with this medication.

Keep your vitamin K intake consistent. I can't emphasize this enough. You don't need to avoid green vegetables. In fact, I encourage you to eat them. Just try to eat roughly the same amount each week. If you're planning a significant dietary change (starting a new diet, for example), let your anticoagulation team know so they can monitor your INR more closely during the transition.

Take warfarin at the same time every day. Consistency helps maintain stable drug levels. Most patients take it in the evening, which is convenient because if your doctor calls with a dose adjustment based on that day's INR, you can implement the change that same night.

Never skip or double up on doses without guidance. If you miss a dose, take it as soon as you remember that same day. If it's the next day, skip the missed dose and resume your regular schedule. Do not take two doses to make up for a missed one. Call your anticoagulation clinic for guidance if you're unsure.

Tell every doctor, dentist, and pharmacist that you're on warfarin. This is true for any blood thinner, but it's especially important with warfarin because of the extensive drug interaction list. Before starting any new prescription, over-the-counter medication, or herbal supplement, check with your anticoagulation provider.

Avoid NSAIDs (ibuprofen, naproxen) when possible. These anti-inflammatory medications increase bleeding risk significantly when combined with warfarin. Acetaminophen (Tylenol) is generally a safer alternative for pain relief, though even high-dose acetaminophen can affect INR if used regularly.

Wear a medical alert bracelet or carry a card. In an emergency, paramedics and ER physicians need to know you're on an anticoagulant. This information can change the entire treatment approach, particularly for head injuries or surgical emergencies.

Don't stop warfarin without talking to your doctor. Abruptly stopping anticoagulation can cause a rebound increase in clotting risk. If you need to stop warfarin for a procedure or surgery, your doctor will create a bridging plan (often involving short-acting injectable heparin) to keep you protected during the transition.

Warfarin and Alcohol

I get this question frequently. Moderate alcohol consumption (one drink per day for women, up to two for men) is generally acceptable on warfarin, but consistency matters here too. Alcohol affects warfarin metabolism in the liver, and binge drinking can cause dangerous INR elevations. Chronic heavy drinking also impairs liver function, which compounds the problem. My advice: if you drink, keep it moderate and consistent. Avoid binge drinking entirely.

When It Might Be Time to Switch from Warfarin to a DOAC

For patients currently on warfarin who don't have one of the specific indications listed above (mechanical valve, APS, rheumatic mitral stenosis, severe kidney disease), it's reasonable to discuss switching to a DOAC with your cardiologist. This is especially worth considering if your TTR is consistently below 65%, meaning your INR is frequently out of range despite best efforts. Studies have shown that patients with poor TTR on warfarin derive greater benefit from switching to a DOAC than patients whose warfarin is well managed.

The switch itself is straightforward. For most DOACs, you simply stop warfarin and start the DOAC once your INR drops below 2.0. Your doctor will provide specific instructions based on which DOAC you're transitioning to.

However, I also want to acknowledge the opposite scenario. I have patients who have been on warfarin for years, whose INR is consistently in range, who know their diet and medication interactions inside and out, and who are perfectly comfortable with their monitoring routine. For these patients, there may be no compelling reason to switch. Good warfarin management produces outcomes that are very similar to DOACs, and "if it isn't broken, don't fix it" is a reasonable philosophy in medicine.

The Future of Warfarin

Warfarin has been in clinical use since 1954. That's over 70 years. No medication survives that long unless it does something important and does it well. While DOAC prescriptions will continue to grow and warfarin prescriptions will continue to decline for the general population, warfarin isn't going away.

Pharmacogenomic testing (using your CYP2C9 and VKORC1 genetic variants to guide dosing) is becoming more accessible and may improve warfarin management in the future by allowing more precise initial dosing. Home INR monitoring technology continues to improve. And for the specific populations where DOACs have failed or remain untested, warfarin will continue to be the standard of care for the foreseeable future.

Anticoagulation Management in San Diego

At my practice in Encinitas, I take anticoagulation management seriously because the stakes are high. Whether you're on warfarin for a mechanical valve, a history of blood clots, atrial fibrillation, or another condition, the goal is always the same: protect you from dangerous clots while minimizing bleeding risk. That means choosing the right anticoagulant for your specific situation, monitoring it properly, and adjusting the plan as your health changes over time.

If you're currently on warfarin and wondering whether you should switch to a DOAC, or if you've been told you need to start an anticoagulant and want to understand your options, I'm happy to walk through the decision with you. As a board-certified invasive cardiologist at Scripps Memorial Hospital, I see these decisions every day and can help you find the approach that's safest and most practical for your life. Contact us to schedule a consultation.

Frequently Asked Questions About Coumadin (Warfarin)

Is warfarin the same as Coumadin?

Yes. Coumadin is the original brand name for warfarin. The generic version (warfarin sodium) is now what most pharmacies dispense. They are the same medication. One important note: if you've been stable on a specific manufacturer's generic warfarin, try to stay with that manufacturer if possible, as slight differences in formulation between generic manufacturers can occasionally cause small INR fluctuations.

Can I eat green vegetables on warfarin?

Yes, and you should. Leafy greens are excellent for your overall health. The key is consistency. Don't avoid them, but don't dramatically increase or decrease your intake from week to week. Your warfarin dose is calibrated to your usual diet, so keeping it steady is what keeps your INR stable.

How often do I need blood tests on warfarin?

When first starting, you'll need INR checks every few days until your dose stabilizes. Once stable, most patients are tested every two to four weeks. Home INR monitoring devices can reduce the need for office visits while allowing more frequent testing.

What should I do if I miss a dose?

Take it as soon as you remember on the same day. If you don't remember until the next day, skip the missed dose and take your regular dose that evening. Never double up. If you miss more than one dose, contact your anticoagulation provider.

Why can't I just take Eliquis instead?

For many patients, you can, and a DOAC like apixaban (Eliquis) may be the better choice. But if you have a mechanical heart valve, antiphospholipid syndrome, rheumatic mitral stenosis, or severe kidney disease, warfarin is safer and more effective. The best anticoagulant is the one that's right for your specific situation.

Is warfarin dangerous?

All anticoagulants carry bleeding risk, including DOACs. Warfarin's risk is well understood after 70+ years of use, and when managed properly (with good INR control and consistent monitoring), it is a safe and effective medication. The conditions it prevents, like stroke and pulmonary embolism, are far more dangerous than the medication itself.

Can warfarin be reversed in an emergency?

Yes. Warfarin can be reversed with intravenous vitamin K and, for emergencies, with four-factor prothrombin complex concentrate (4F-PCC), which works within minutes. This reliable reversibility is actually one of warfarin's advantages in certain clinical scenarios.

How long will I need to be on warfarin?

This depends entirely on why you're taking it. For a mechanical heart valve, it's lifelong. For a first episode of deep vein thrombosis provoked by a temporary risk factor (like surgery or prolonged immobilization), it may be three to six months. For atrial fibrillation, anticoagulation is generally ongoing. Your cardiologist will reassess periodically whether continued therapy is appropriate.

References

1. Eikelboom JW, Connolly SJ, Brueckmann M, et al. "Dabigatran versus Warfarin in Patients with Mechanical Heart Valves." New England Journal of Medicine 369, no. 13 (2013): 1206-1214.

2. Pengo V, Denas G, Zoppellaro G, et al. "Rivaroxaban vs Warfarin in High-Risk Patients with Antiphospholipid Syndrome (TRAPS)." Blood 132, no. 13 (2018): 1365-1371.

3. Granger CB, Alexander JH, McMurray JJV, et al. "Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE)." New England Journal of Medicine 365, no. 11 (2011): 981-992.

4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. "Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY)." New England Journal of Medicine 361, no. 12 (2009): 1139-1151.

5. Patel MR, Mahaffey KW, Garg J, et al. "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET AF)." New England Journal of Medicine 365, no. 10 (2011): 883-891.

6. Johnson JA, Caudle KE, Gong L, et al. "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update." Clinical Pharmacology and Therapeutics 102, no. 3 (2017): 397-404.

7. Wan Y, Heneghan C, Perera R, et al. "Time in Therapeutic Range for Patients Taking Warfarin in Clinical Trials." Circulation 118 (2008): 2029-2037.

8. Tran M, Curnow J, Ngo A, et al. "2025 Guidelines for Direct Oral Anticoagulants: A Practical Guidance on the Prescription, Laboratory Testing, Peri-operative and Bleeding Management." Internal Medicine Journal (2025).

9. Wadsworth D, Mughal N, Gaillard N. "A Review of Indications and Comorbidities in Which Warfarin May Be the Preferred Oral Anticoagulant." Journal of Clinical Pharmacy and Therapeutics 46, no. 3 (2021): 560-570.

10. January CT, Wann LS, Calkins H, et al. "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation." Circulation 140, no. 2 (2019): e125-e151.

Published on damianrasch.com. Written by Dr. Damian Rasch, D.O., board-certified invasive cardiologist. This content is for informational purposes only and does not constitute medical advice. Always consult your physician regarding your specific medical condition.